I introduced the term “Typo-gate” to describe a controversy at Alnylam Pharmaceuticals where executives accused cardiologist Sarah Cuddy of making errors in her discussant’s talk on the vutrisiran HELIOS-B study results. However, it was later revealed that Cuddy’s analysis comparing vutrisiran and a competitor drug was correct. Cuddy, a cardiologist at Brigham and Women’s Hospital, compared all-cause mortality data from both drugs’ placebo-controlled Phase 3 studies in ATTR-CM. This revelation highlights the importance of thorough analysis and the potential consequences of jumping to conclusions without proper evaluation.
Source link
Alnylam versus BridgeBio: The ATTR-CM debate
